Ziltivekimab for Treatment of Anemia of Inflammation in Patients on Hemodialysis: Results from a Phase 1/2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

BACKGROUND: Patients with CKD who are on hemodialysis are hyporesponsive to erythropoiesis-stimulating agents (ESAs) because of anemia of inflammation. Interleukin-6 (IL-6) induced hepcidin expression is a key mediator of such inflammation. METHODS: This phase 1/2, placebo-controlled trial assessed...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Am Soc Nephrol
Main Authors: Pergola, Pablo E., Devalaraja, Matt, Fishbane, Steven, Chonchol, Michel, Mathur, Vandana S., Smith, Mark T., Lo, Larry, Herzog, Kurt, Kakkar, Rahul, Davidson, Michael H.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Nephrology 2021
Assuntos:
Clinical Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7894678/
https://ncbi.nlm.nih.gov/pubmed/33272965
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1681/ASN.2020050595
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados